Description
BSE notifies trading members that 7,32,000 equity shares of Goldline Pharmaceutical Limited have been allocated to Anchor Investors at Rs. 43 per share under its public issue.
Summary
BSE has informed trading members that under the Anchor Investors (AIs) portion of the Public Issue of Goldline Pharmaceutical Limited, 7,32,000 equity shares have been subscribed on May 11, 2026, at a price of Rs. 43 per equity share.
Key Points
- 7,32,000 equity shares allocated to Anchor Investors in the public issue of Goldline Pharmaceutical Limited
- Anchor Investor subscription price fixed at Rs. 43 per equity share
- Allocation occurred on May 11, 2026
- Notice issued by BSE’s Listing Business Relationship Department
- A copy of the Company’s Announcement dated May 11, 2026 is enclosed with the circular
Regulatory Changes
No regulatory changes. This is a procedural notification regarding anchor investor allocation as part of the standard IPO process.
Compliance Requirements
Trading members are informed for awareness purposes. No specific compliance action is required from members in response to this circular.
Important Dates
- May 11, 2026: Date of anchor investor subscription and BSE notice issuance
Impact Assessment
The anchor investor allocation at Rs. 43 per share establishes the IPO price point and signals institutional interest in Goldline Pharmaceutical Limited. The allocation of 7,32,000 shares to anchor investors is a standard pre-IPO step and indicates the issue is progressing as scheduled. Impact is limited to investors and market participants tracking this specific IPO.
Impact Justification
Routine anchor investor allocation notice for an upcoming IPO; relevant to investors tracking Goldline Pharmaceutical's public issue but has no broad market or regulatory impact.